Brief: Labcorp Launches Molecular Residual Disease And Liquid Biopsy Solutions
April 23 (Reuters) - Labcorp Holdings Inc LH.N: LABCORP LAUNCHES MOLECULAR RESIDUAL DISEASE AND LIQUID BIOPSY SOLUTIONS LABCORP HOLDINGS - PLASMA DETECT NOW AVAILABLE FOR CLINICAL USE TO ASSESS RISK OF RECURRENCE IN STAGE III COLON CANCER PATIENTS Source text: ID:nPnXwmPma Further company coverage: LH.N ((reuters.briefs@thomsonreuters.com;))
Recent news on Labcorp Holdings
See all newsBrief: Charles River, Labcorp, And FDA Collaborate To Validate New Preclinical Methods For Abuse Potential Assessment
Brief: Labcorp Declares Quarterly Dividend
Myriad jumps after agreeing to sell prenatal health testing business
Brief: Myriad Genetics To Sell Prenatal Health Testing Business To Labcorp
Live Markets: Split US congress after 2026 midterms could boost healthcare stocks, Mizuho says